Accelerated Adoption of Guardant360 Tissue ASP Achieving 2028 Target Three Years Early
Guardant360 Tissue ASP reached approximately $2,000 in Q2, surpassing the 2028 target three years ahead of schedule.
Major upgrade in April expanded the panel to include RNA and methylome analysis, with 40% fewer slides than industry norm, serving as a key differentiator.
Strategic Merger of Pelthos and Channel Therapeutics
The merger involved a reverse merger process, creating a new public entity, Pelthos Therapeutics, which launched Zelsuvmi, a treatment for Molluscum contagiosum.
Pelthos's market forecast suggests capturing fewer than 100,000 patients in a 16.7 million patient market, with potential royalties of around $23 million annually in the U.S.
Ligand's strategic ownership of the nitric oxide platform and pipeline of late-stage programs offers multiple future royalty streams, emphasizing its focus on high-value assets.
Recognition of Top-Ranked Rehabilitation Hospitals and Strategic Development Achievements
Eight hospitals recognized among the nation's best by U.S. News & World Report, with Kessler Institute for Rehabilitation ranked #4 for 33rd consecutive year.
Opened new facilities including a 12-bed hospital with UPMC in Pennsylvania, a neuro transitional care unit in Missouri, and expansions in Florida.
Plans to open multiple new hospitals in 2026 and 2027, including partnerships with Banner Health and Cox Health Systems, with a focus on high-demand markets.
FDA Breakthrough Designation for DecisionDx-Melanoma and Strategic Path to FDA Approval
Castle Biosciences received FDA Breakthrough Device Designation for DecisionDx-Melanoma, signaling a significant regulatory milestone.
The company is actively progressing towards an FDA submission, with no specific public timeline disclosed.
Management expressed confidence that existing data supports FDA approval, emphasizing the importance of the breakthrough designation in accelerating regulatory pathway.
Dafinchi
